archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Guidelines for Inclusion of Drug Costs | National Centre for Pharmacoeconomics
    Pharmacoeconomic Research ICORN Education Guidelines for Inclusion of Drug Costs In this Section Submission Process HTA Guidelines Guidelines for Inclusion of Drug Costs Critical appraisal criteria Process Flowchart Submission Templates Rapid Review Template Full Submission Template New Medicine Horizon Scanning The purpose of this document is to provide guidance for inclusion of costs for the drug of interest its comparator s and concomitant drugs in pharmacoeconomic evaluations Drug costs should

    Original URL path: http://www.ncpe.ie/submission-process/hta-guidelines/guidelines-for-inclusion-of-drug-costs/ (2015-10-30)
    Open archived version from archive


  • Critical appraisal criteria | National Centre for Pharmacoeconomics
    Costs Critical appraisal criteria Process Flowchart Submission Templates Rapid Review Template Full Submission Template New Medicine Horizon Scanning A brief summary of relevant questions that may be posed in relation to economic evaluations is shown below Of course it is unrealistic to expect every study to satisfy all of the 10 points however the systematic application of these points will allow readers to identify and assess the strengths and weaknesses

    Original URL path: http://www.ncpe.ie/submission-process/hta-guidelines/critical-appraisal-criteria/ (2015-10-30)
    Open archived version from archive

  • Rapid Review Template | National Centre for Pharmacoeconomics
    ICORN Education Rapid Review Template In this Section Submission Process HTA Guidelines Guidelines for Inclusion of Drug Costs Critical appraisal criteria Process Flowchart Submission Templates Rapid Review Template Full Submission Template New Medicine Horizon Scanning This template to be completed by manufacturers is intended to provide a summary of information to facilitate the rapid review process A typical submission would be no longer than five pages long Further information may

    Original URL path: http://www.ncpe.ie/submission-process/submission-templates/rapid-review-template/ (2015-10-30)
    Open archived version from archive

  • Full Submission Template | National Centre for Pharmacoeconomics
    Template New Medicine Horizon Scanning Applicant template This document outlines the content and format of the written submission to the NCPE as part of a full pharmacoeconomic assessment Download NCPE requirements for conducting and reporting clinical evidence synthesis analysis This document outlines the NCPE requirements for the conduct and reporting of clinical evidence synthesis analyses submitted to the NCPE as part of a full pharmacoeconomic assessment Section 3 ii of

    Original URL path: http://www.ncpe.ie/submission-process/submission-templates/format-of-full-submissions/ (2015-10-30)
    Open archived version from archive

  • New Medicine Horizon Scanning | National Centre for Pharmacoeconomics
    In this Section Submission Process HTA Guidelines Guidelines for Inclusion of Drug Costs Critical appraisal criteria Process Flowchart Submission Templates Rapid Review Template Full Submission Template New Medicine Horizon Scanning This template has been developed in consultation with IPHA HSE NCCP and the NCPE It is intended that the document be submitted to each unit where relevant The completed document is intended to enable the HSE NCPE and NCCP to

    Original URL path: http://www.ncpe.ie/submission-process/submission-of-new-medicine-horizon-scan-by-manufacturers/ (2015-10-30)
    Open archived version from archive

  • Latest Drugs | National Centre for Pharmacoeconomics
    Drugs In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Netupitant palonosetron Akynzeo October 13 2015 Insulin Glargine Abasaglar October 12 2015 Ibrutinib Imbruvica for MCL October 7 2015 Ibrutinib Imbruvica for CLL October 1 2015 Lidocaine 5 plasters Versatis September 24 2015 Secukinumab Cosentyx September 16 2015 Pertuzumab Perjeta in neoadjuvant HER2 positive breast cancer September 1 2015 Evolocumab Repatha August 14 2015 Pembrolizumab

    Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/ (2015-10-30)
    Open archived version from archive

  • Archive | National Centre for Pharmacoeconomics
    RoActemra Defibrotide Defitelio Simeprevir Olysio Umeclidinium vilanterol Anoro Bosentan Tracleer Ambrisentan Volibris Alemtuzumab Lemtrada Trastuzumab emtansine Kadcyla Dabrafenib Tafinlar Regorafenib Stivarga for mCRC Buprenorphine naloxone Suboxone Teriflunomide Aubagio Omalizumab Xolair Dabigatran Etexilate Pradaxa for the treatment of DVT and PE Empagliflozin Jardiance Tadalafil Adcirca Sildenafil Revatio Riociguat Adempas Brimonidine 3 3 mg g gel Mirvaso Clindamycin 1 with tretinoin 0 025 Treclinac Oladaterol Striverdi Respimat Avanafil Spedra Brentuximab vedotin Adcetris Enzalutamide Xtandi on or after chemotherapy Nalmefene Selincro Sodium Chloride 70mg ml Sodium Hyaluronate 1mg ml Hyaneb Dolutegravir Tivicay Abiraterone acetate Zytiga for mCRPC post ADT Incobotulinum Toxin Type A Xeomin Eltrombopag Revolade Aflibercept Zaltrap Macitentan Opsumit Liquid Paraffin Ointment VitA POS Opthalmic Sodium Hyaluronate Hyloforte 0 2 Sodium Hyaluronate Hylotear 0 1 Vismodegib Erivedge 2013 Levodopa 20mg ml carbidopa monohydrate 5mg intestinal gel Duodopa Dapagliflozin Forxiga Fluticasone furoate vilanterol Relvar Ellipta Ponatinib Iclusig Abatacept Orencia Alogliptin Vipidia Golimumab Simponi for UC Pregabalin Lyrica for the treatment of neuropathic pain Ulipristal acetate Esmya Afatinib Giotrif Eculizumab Soliris Bosutinib Bosulif Lipegfilgrastim Lonquex Infliximab Inflectra Imiquimod 3 75 Zyclara Modified Release Hydrocortisone Plenadren Pertuzumab Perjeta Crizotinib Xalkori Rifaximin Targaxan Sodium phenylbutyrate Pheburane Icatibant Firazyr Perampanel Fycompa Ruxolitinib Jakavi Ocriplasmin Jetrea Linaclotide Constella Colistimethate sodium Colobreathe Vandetanib Caprelsa Apixaban Eliquis for the prevention of stroke and systemic embolism in patients with non valvular atrial fibrillation Elvitegravir cobicistat emtricitabine tenofovir disoproxil as fumarate Stribild Omega 3 acid ethyl esters Omacor Levonorgestrel Intrauterine System LNG IUS Jaydess Pirfenidone Esbriet Lisdexamfetamine dimesylate Tyvense Azelastine hydrochloride and fluticasone propionate nasal spray Dymista Fidaxomicin Dificlir Ivacaftor Kalydeco Mirabegron Betmiga 2012 Aflibercept Eylea Decitabine Dacogen Bendamustine Levact Eribulin Halaven Ingenol mebutate gel Picato Axitinib Inlyta C1inhibitor human Cinryze Aclidinium bromide Eklira Genuair Everolimus Afinitor Ceftaroline Zinforo Vemurafenib Zelboraf Fampridine Fampyra Ferumoxytol Rienso Glycopyrronium bromide Seebri Breezhaler Capsaicin 8 w

    Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/archive/ (2015-10-30)
    Open archived version from archive

  • A | National Centre for Pharmacoeconomics
    Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Drugs A In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive A B C D E F G H I L M N O P R S T U V Abatacept Orencia Abiraterone Acetate Zytiga for mCRPC Abiraterone acetate Zytiga for mCRPC post ADT Aclidinium bromide Eklira Genuair Aclidinium bromide formoterol fumarate dihydrate Brimica Genuair Adalimumab

    Original URL path: http://www.ncpe.ie/category/drugs/a-drugs/ (2015-10-30)
    Open archived version from archive